STAT3 and lung carcinoma: Antiparasitic drugs have been demonstrated to successfully inhibit the activation of the STAT3 pathway, selectively impairing the growth of lung cancer cells and eliciting lethal effects both in vitro and in vivo [28,35,36,37].